Non-viral strategies for ocular gene delivery
- PMID:28532005
- DOI: 10.1016/j.msec.2017.04.068
Non-viral strategies for ocular gene delivery
Abstract
The success of gene therapy relies on efficient gene transfer and stable transgene expression. The in vivo efficiency is determined by the delivery vector, route of administration, therapeutic gene, and target cells. While some requirements are common to several strategies, others depend on the target disease and transgene product. Consequently, it is unlikely that a single system is suitable for all applications. This review examines current gene therapy strategies, focusing on non-viral approaches and the use of natural polymers with the eye, and particularly the retina, as their gene delivery target.
Keywords: Eye; Gene therapy; Non-viral vectors; Retina.
Copyright © 2017 Elsevier B.V. All rights reserved.
Similar articles
- Self-focusing therapeutic gene delivery with intelligent gene vector swarms: intra-swarm signalling through receptor transgene expression in targeted cells.Tolmachov OE.Tolmachov OE.Artif Intell Med. 2015 Jan;63(1):1-6. doi: 10.1016/j.artmed.2014.11.001. Epub 2014 Dec 17.Artif Intell Med. 2015.PMID:25547266
- Treatment of ocular disorders by gene therapy.Solinís MÁ, del Pozo-Rodríguez A, Apaolaza PS, Rodríguez-Gascón A.Solinís MÁ, et al.Eur J Pharm Biopharm. 2015 Sep;95(Pt B):331-42. doi: 10.1016/j.ejpb.2014.12.022. Epub 2014 Dec 20.Eur J Pharm Biopharm. 2015.PMID:25536112Review.
- Current status of gene delivery and gene therapy in lacrimal gland using viral vectors.Selvam S, Thomas PB, Hamm-Alvarez SF, Schechter JE, Stevenson D, Mircheff AK, Trousdale MD.Selvam S, et al.Adv Drug Deliv Rev. 2006 Nov 15;58(11):1243-57. doi: 10.1016/j.addr.2006.07.021. Epub 2006 Sep 15.Adv Drug Deliv Rev. 2006.PMID:17056149Free PMC article.Review.
- Non-viral retinal gene therapy: a review.Charbel Issa P, MacLaren RE.Charbel Issa P, et al.Clin Exp Ophthalmol. 2012 Jan-Feb;40(1):39-47. doi: 10.1111/j.1442-9071.2011.02649.x. Epub 2011 Sep 19.Clin Exp Ophthalmol. 2012.PMID:21745262Review.
- Controlling the kinetics of interferon transgene expression for improved gene therapy.Watcharanurak K, Nishikawa M, Takahashi Y, Takakura Y.Watcharanurak K, et al.J Drug Target. 2012 Nov;20(9):764-9. doi: 10.3109/1061186X.2012.716848. Epub 2012 Sep 20.J Drug Target. 2012.PMID:22994266Review.
Cited by
- An Update on Mesoporous Silica Nanoparticle Applications in Nanomedicine.Rastegari E, Hsiao YJ, Lai WY, Lai YH, Yang TC, Chen SJ, Huang PI, Chiou SH, Mou CY, Chien Y.Rastegari E, et al.Pharmaceutics. 2021 Jul 12;13(7):1067. doi: 10.3390/pharmaceutics13071067.Pharmaceutics. 2021.PMID:34371758Free PMC article.Review.
- Viral-Vector-Delivered Anti-Angiogenic Therapies to the Eye.Koponen S, Kokki E, Kinnunen K, Ylä-Herttuala S.Koponen S, et al.Pharmaceutics. 2021 Feb 5;13(2):219. doi: 10.3390/pharmaceutics13020219.Pharmaceutics. 2021.PMID:33562561Free PMC article.Review.
- A method for gene knockdown in the retina using a lipid-based carrier.Chu-Tan JA, Fernando N, Aggio-Bruce R, Cioanca AV, Valter K, Andronikou N, deMollerat du Jeu X, Rutar M, Provis J, Natoli R.Chu-Tan JA, et al.Mol Vis. 2020 Feb 24;26:48-63. eCollection 2020.Mol Vis. 2020.PMID:32165826Free PMC article.
- Non-viral gene therapy for Leber's congenital amaurosis: progress and possibilities.Abdulsalam L, Mordecai J, Ahmad I.Abdulsalam L, et al.Nanomedicine (Lond). 2025 Feb;20(3):291-304. doi: 10.1080/17435889.2024.2443387. Epub 2024 Dec 20.Nanomedicine (Lond). 2025.PMID:39707712Review.
- Intracameral Delivery of Layer-by-Layer Coated siRNA Nanoparticles for Glaucoma Therapy.Dillinger AE, Guter M, Froemel F, Weber GR, Perkumas K, Stamer WD, Ohlmann A, Fuchshofer R, Breunig M.Dillinger AE, et al.Small. 2018 Dec;14(50):e1803239. doi: 10.1002/smll.201803239. Epub 2018 Oct 23.Small. 2018.PMID:30353713Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources